Pharmaceutics International, Inc. Sustainability Profile
Pharmaceutics International, Inc. (PII), headquartered in the United States, is a leading player in the pharmaceutical contract development and manufacturing industry. Founded in 1997, the company has established a strong presence in key operational regions, including North America and Europe. PII specialises in the formulation and production of complex drug products, particularly in the areas of injectable and oral dosage forms. With a commitment to innovation, Pharmaceutics International offers unique services such as customised formulation development and comprehensive analytical testing. The company has achieved notable milestones, including successful partnerships with major pharmaceutical firms, which solidify its market position as a trusted provider in the industry. PII's dedication to quality and regulatory compliance sets it apart, making it a preferred choice for clients seeking reliable pharmaceutical solutions.
DitchCarbon Score
How does Pharmaceutics International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmaceutics International, Inc.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmaceutics International, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Jabil Inc., which may influence its climate commitments and reporting practices. Pharmaceutics International, Inc. has not established any documented reduction targets or specific climate pledges. However, as part of its corporate family, it may align with the sustainability initiatives and targets set by Jabil Inc. This includes potential commitments to the Science Based Targets initiative (SBTi) and other climate-related frameworks, although specific details regarding these initiatives are not provided. As the company continues to develop its sustainability strategy, it is essential to monitor any future disclosures that may outline its carbon emissions and climate commitments more clearly.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 37,100,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 1,182,767,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 51,478,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Pharmaceutics International, Inc.'s Industry?
How Carbon Intensive is Pharmaceutics International, Inc.'s Location?
Pharmaceutics International, Inc.'s Scope 3 Categories Breakdown
Pharmaceutics International, Inc.'s Scope 3 emissions, which decreased by 13% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 86% of Scope 3 emissions.
Top Scope 3 Categories
Pharmaceutics International, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmaceutics International, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
